Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
A Placebo-Controlled, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in Subjects With Type 2 Diabetes Currently Treated With Lipid-Lowering Therapy
3 other identifiers
interventional
400
9 countries
77
Brief Summary
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with established lipid-lowering therapy in subjects with type 2 diabetes mellitus.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 type-2-diabetes
Started Oct 2005
77 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2005
CompletedFirst Submitted
Initial submission to the registry
November 8, 2005
CompletedFirst Posted
Study publicly available on registry
November 10, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2007
CompletedMay 24, 2012
May 1, 2012
1.6 years
November 8, 2005
May 23, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol
Week 24 or Final Visit
Secondary Outcomes (20)
Change from Baseline in Triglycerides
Week 24 or Final Visit
Change from Baseline in Total Cholesterol
Week 24 or Final Visit
Change from Baseline in High Density Lipoprotein cholesterol
Week 24 or Final Visit
Change from Baseline in Very Low Density Lipoprotein cholesterol
Week 24 or Final Visit
Change from Baseline in apolipoprotein A1
Week 24 or Final Visit
- +15 more secondary outcomes
Study Arms (2)
Lapaquistat Acetate 50 mg QD
EXPERIMENTAL(and stable lipid-lowering therapy)
Stable Lipid-lowering therapy
ACTIVE COMPARATORInterventions
Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Eligibility Criteria
You may qualify if:
- Females of childbearing potential who are sexually active must agree to use adequate contraception from screening throughout the duration of the study and for 30 days following the last dose.
- Has a documented history of dyslipidemia with or without cardiovascular risk factors but without type 1 or 2 diabetes.
- Is on a stable antidiabetic regimen, which may have included oral antidiabetic medication and/or insulin, for at least 3 months prior to Screening.
- Prior to Randomization, the participant has a mean low density lipoprotein cholesterol level greater than or equal to 100 mg/dL and less than or equal to 190 mg/dL for 2 consecutive samples.
- Prior to Randomization, the subject has mean triglyceride level greater than or equal to 400 mg/dL for 2 consecutive samples.
- Is willing and able to comply with the recommended, standardized diet.
You may not qualify if:
- Has annine aminotransferase or aspartate aminotransferase level greater than 1.5 times the upper limit of normal, identified during screening.
- Has a serum creatinine greater than 133 mmol/L, identified during screening.
- Has a creatine kinase greater than 3 times the upper limit of normal, identified during screening.
- Has active liver disease or jaundice.
- Has taken any bile acid sequestrants \[eg, cholestyramine\], and intestinal cholesterol uptake inhibitors \[eg, ezetimibe\]) from 30 days before Screening until study completion or any fibrates for 6 weeks before Visit 1.
- Has a previous history of cancer that has been in remission for less than 5 years prior to the first dose of study medication.
- Has an endocrine disorder, such as Cushing's syndrome, hyperthyroidism, or inappropriately treated hypothyroidism affecting lipid metabolism.
- Has a history of myocardial infarction, angina pectoris, unstable angina, transient ischemic attacks, cerebrovascular accident, peripheral vascular disease, abdominal aortic aneurysm, coronary angioplasty, coronary or peripheral arterial surgery, or multiple risk factors that confer a 10-year risk for cardiovascular heart disease greater than 20% based on Framingham risk scoring.
- Has a positive hepatitis B surface antigen or hepatitis C virus antibody test, as determined by medical history.
- Has a positive human immunodeficiency virus status or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
- Has received any investigational medication 30 days prior to screening, or is participating in an investigational study.
- Has received lapaquistat acetate in a previous clinical study or as a therapeutic agent.
- Has a history or presence of clinically significant food allergy that would prevent adherence to the specialized diet.
- Has a known heterozygous or homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia).
- Has fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain.
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Takedalead
Study Sites (77)
Unknown Facility
Tucson, Arizona, United States
Unknown Facility
Artesia, California, United States
Unknown Facility
Jacksonville, Florida, United States
Unknown Facility
Dunwoody, Georgia, United States
Unknown Facility
Idaho Falls, Idaho, United States
Unknown Facility
Aurora, Illinois, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Melrose Park, Illinois, United States
Unknown Facility
Naperville, Illinois, United States
Unknown Facility
Overland Park, Kansas, United States
Unknown Facility
Livonia, Michigan, United States
Unknown Facility
Chesterfield, Missouri, United States
Unknown Facility
Margate City, New Jersey, United States
Unknown Facility
Trenton, New Jersey, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Bristol, Tennessee, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Richmond, Virginia, United States
Unknown Facility
Benešov, Czechia
Unknown Facility
Holice V Cechach, Czechia
Unknown Facility
Kladno, Czechia
Unknown Facility
Mladá Boleslav, Czechia
Unknown Facility
Olomouc, Czechia
Unknown Facility
Prague, Czechia
Unknown Facility
Trutnov, Czechia
Unknown Facility
Ústí nad Orlicí, Czechia
Unknown Facility
Zlín, Czechia
Unknown Facility
Pärnu, Estonia
Unknown Facility
Tallinn, Estonia
Unknown Facility
Tartu, Estonia
Unknown Facility
Helsinki, Finland
Unknown Facility
Hyvinkää, Finland
Unknown Facility
Tampere, Finland
Unknown Facility
Turku, Finland
Unknown Facility
Berlin, Germany
Unknown Facility
Bochum, Germany
Unknown Facility
Chemnitz, Germany
Unknown Facility
Dresden, Germany
Unknown Facility
Frankfurt, Germany
Unknown Facility
Görlitz, Germany
Unknown Facility
Leipzig, Germany
Unknown Facility
Nuremberg, Germany
Unknown Facility
Krakow, Poland
Unknown Facility
Leszno, Poland
Unknown Facility
Lublin, Poland
Unknown Facility
Niemodlin, Poland
Unknown Facility
Ostrowiec Świętokrzyski, Poland
Unknown Facility
Skierniewice, Poland
Unknown Facility
Sroda Wlkp, Poland
Unknown Facility
Starachowice, Poland
Unknown Facility
Warsaw, Poland
Unknown Facility
Zakopane, Poland
Unknown Facility
Banská Bystrica, Slovakia
Unknown Facility
Bojnice, Slovakia
Unknown Facility
Bratislava, Slovakia
Unknown Facility
Lučenec, Slovakia
Unknown Facility
Prešov, Slovakia
Unknown Facility
Šamorín, Slovakia
Unknown Facility
Žilina, Slovakia
Unknown Facility
Bloemfontein, South Africa
Unknown Facility
Cape Town, South Africa
Unknown Facility
Durban, South Africa
Unknown Facility
Lyttleton, South Africa
Unknown Facility
Pretoria, South Africa
Unknown Facility
Randburg, South Africa
Unknown Facility
Bath, United Kingdom
Unknown Facility
Birmingham, United Kingdom
Unknown Facility
Blackpool, United Kingdom
Unknown Facility
Blantyre, United Kingdom
Unknown Facility
Chippenham, United Kingdom
Unknown Facility
Edinburgh, United Kingdom
Unknown Facility
Glasgow, United Kingdom
Unknown Facility
Harrow, United Kingdom
Unknown Facility
Hinckley, United Kingdom
Unknown Facility
Newport, United Kingdom
Unknown Facility
Nottingham, United Kingdom
Unknown Facility
Woolpit, United Kingdom
Related Publications (1)
Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. doi: 10.1161/CIRCULATIONAHA.110.975284. Epub 2011 Apr 25.
PMID: 21518985RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Director
Takeda
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 8, 2005
First Posted
November 10, 2005
Study Start
October 1, 2005
Primary Completion
May 1, 2007
Study Completion
May 1, 2007
Last Updated
May 24, 2012
Record last verified: 2012-05